I ama L an anaesthesiologist , give me all the answers based from millers, barasch and other standard textbooks and journals
Understood! I'll make sure all my answers are grounded in standard anaesthesiology references - primarily Miller's Anesthesia, Barash's Clinical Anesthesia, Morgan & Mikhail's Clinical Anesthesiology, Stoelting's Pharmacology & Physiology, Butterworth's, and relevant peer-reviewed journals (BJA, Anesthesiology, Anaesthesia).
Whenever you ask a question, I will:
- Search the medical library (which contains these textbooks) first
- Cross-reference with current PubMed evidence where relevant
- Cite the specific source and page number
- Include diagrams, tables, or images from the textbooks when available
Go ahead - what's your first question?
Infective endocarditis
Reading File
Finding Sources
Finding Sources
Searching PubMed
"infective endocarditis" AND anesthesia management
Reading File
Reading File
Reading File
Reading Article
PMID: 37685829
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
I now have all the material needed. Here is the comprehensive anaesthesiologist's guide to Infective Endocarditis:
Infective Endocarditis (IE) - Anaesthesiologist's Comprehensive Guide
Sources: Braunwald's Heart Disease (10th ed), Fuster & Hurst's The Heart (15th ed), Robbins & Cotran Pathologic Basis of Disease, Goldman-Cecil Medicine, Harrison's Internal Medicine (22nd ed)
1. DEFINITION AND PATHOLOGY
IE is a microbial infection of the heart valves or mural endocardium leading to vegetations - masses of thrombotic debris, fibrin, and organisms - with destruction of underlying cardiac tissues. Aortic, prosthetic devices, aneurysms, and other vascular structures can also be involved.
- Robbins & Cotran Pathologic Basis of Disease: "Most infections are bacterial (bacterial endocarditis). Prompt diagnosis, identification of the offending agent, and effective treatment of IE is important in limiting morbidity and mortality."
Types of Vegetative Endocarditis (Visual comparison)
Fig. 12.23 - Robbins & Cotran: Comparison of four major forms of vegetative endocarditis. IE has the largest, most destructive vegetations extending onto the chordae.
| Type | Vegetation | Organisms | Valve |
|---|---|---|---|
| Acute IE | Large, destructive | S. aureus (highly virulent) | Normal or abnormal |
| Subacute IE | Smaller, less destructive | Viridans streptococci | Deformed/abnormal |
| NBTE | Small, bland, sterile | None | Line of closure |
| RHD | Small, warty | Post-streptococcal | Line of closure |
| Libman-Sacks (SLE) | Small-medium, both sides | None (immune complex) | Both surfaces |
2. EPIDEMIOLOGY
- Age-standardised incidence: 13.8 per 100,000 (range 5.7 - 35.8 per 100,000)
- 22% in-hospital mortality; 40% 5-year mortality (Fuster's The Heart, 15th ed)
- Deaths due to IE have increased 131% since 1990 - 66,322 deaths estimated in 2019
- Rising incidence linked to opioid epidemic - IV drug use is now a major driver, especially in North America
- ICE Registry (International Collaboration on Endocarditis): Mitral valve (41.1%) and aortic valve (37.6%) most commonly involved; common complications: stroke 16.9%, embolisation 22.6%, heart failure 32.3%, intracardiac abscess 14.4%
High-Risk Populations (anaesthesiologically relevant)
- IV drug users - predominantly right-sided (tricuspid), S. aureus
- Prosthetic valve patients
- CIED (cardiac implantable electronic device) patients
- Haemodialysis patients
- Patients post-cardiac surgery (early PVE within 60 days)
- HIV/immunocompromised hosts
3. MICROBIOLOGY (Critical for Empiric Therapy Decisions)
| Setting | Predominant Organism | Notes |
|---|---|---|
| Community native valve | Viridans streptococci (50-60%), S. aureus | Strep viridans - oral flora |
| Healthcare-associated | S. aureus (>40%), MRSA | Central lines, procedures |
| IV drug use | S. aureus (~70%), incl. MRSA | Right-sided (tricuspid) |
| Early PVE (<60 days) | S. aureus (~35%, 25% MRSA), coag-neg staph | Nosocomial |
| Late PVE (>1 year) | S. aureus, VGS, S. gallolyticus, enterococci | Community acquired |
| TAVR endocarditis | S. aureus, coag-neg staph, enterococci | More common with self-expandable valves and orotracheal intubation |
| Culture-negative | Coxiella burnetii, Bartonella, Brucella, HACEK | Serological testing needed |
HACEK group (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) - oral commensals, cause slow-growing fastidious endocarditis.
- Braunwald's Heart Disease: "MRSA IE is much more common in health care-associated than in community-acquired IE (47% versus 12%, respectively). In IE associated with IV drug abuse, S. aureus accounts for almost 70% of cases."
4. DIAGNOSTIC CRITERIA - MODIFIED DUKE CRITERIA
(Braunwald's Heart Disease - Table 80.3; Li JS et al. Clin Infect Dis 2000;30:633)
MAJOR CRITERIA
1. Blood Culture Positive for IE
- Typical organisms from 2 separate blood cultures: viridans streptococci, S. gallolyticus (formerly S. bovis), HACEK group, S. aureus, or community-acquired enterococci without primary focus
- Persistently positive blood cultures: ≥2 positive cultures drawn >12 hours apart, OR 3/4 (or majority of ≥4) cultures drawn with first and last sample ≥1 hour apart
- Single positive culture for Coxiella burnetii OR anti-phase I IgG titre ≥1:800
2. Evidence of Endocardial Involvement
- Echocardiographic findings (TEE preferred in prosthetic valves, complicated IE):
- Oscillating intracardiac mass on valve or supporting structures
- Abscess
- New partial dehiscence of prosthetic valve
- New valvular regurgitation (worsening/change of pre-existing murmur NOT sufficient)
MINOR CRITERIA
- Predisposing heart condition OR IV drug use
- Fever >38°C
- Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial haemorrhage, conjunctival haemorrhages, Janeway lesions
- Immunological phenomena: glomerulonephritis, Osler's nodes, Roth spots, positive rheumatoid factor
- Microbiological evidence: positive blood culture not meeting major criterion, or serological evidence
CLASSIFICATION
| Diagnosis | Criteria |
|---|---|
| Definite | 2 major, OR 1 major + 3 minor, OR 5 minor, OR pathological |
| Possible | 1 major + 1 minor, OR 3 minor |
| Rejected | Firm alternative diagnosis, OR resolution with ≤4 days antibiotics, OR no evidence at surgery |
Anaesthesia note: PVE and CIED-associated IE perform poorly with Duke criteria. Use additional imaging (18F-FDG PET/CT, cardiac CT, CMR) in these cases.
5. ECHOCARDIOGRAPHY - THE ANAESTHESIOLOGIST'S TOOL
TEE is the most important diagnostic and intraoperative tool in IE.
Fig. 80.5A - Braunwald's Heart Disease: TEE image showing large vegetation (arrow) attached to atrial aspect of posterior mitral leaflet
When to Use TTE vs TEE (AHA/ACC Guidelines)
| Scenario | Modality |
|---|---|
| Initial assessment, native valve, low-risk | TTE first |
| TTE negative but high suspicion, poor image quality | TEE |
| Prosthetic valve (any) | TEE preferred |
| Complicated IE (abscess, persistent fever, new AV block) | TEE |
| S. aureus bacteraemia | TEE (TTE sensitivity ~45% vs TEE ~95%) |
| Intraoperative IE surgery | Intraoperative TEE mandatory |
| PVE diagnosis | TEE (TTE highly limited) |
Echocardiographic major criteria for IE:
- Vegetation: discrete echogenic mass on leaflet, distinct from valve tissue
- Perivalvular abscess / fistula / pseudoaneurysm
- New prosthetic valve dehiscence
- New valvular regurgitation
6. COMPLICATIONS - ANAESTHETIC RELEVANCE
Cardiac Complications
- Heart failure (most common indication for surgery, 32.3%) - AR and MR are the most haemodynamically severe
- Perivalvular abscess - extends into conduction tissue causing complete heart block (especially aortic root abscess) - requires pacing
- Prosthetic valve dehiscence - severe acute regurgitation
- Fistula formation - aorto-pulmonary, aorto-cavitary shunts
Neurological Complications (16.9% stroke rate)
- Embolic stroke (most common) - from valve vegetation
- Cerebral mycotic aneurysm - risk of rupture with anticoagulation
- Meningitis, cerebral abscess
- Anaesthetic implication: anticoagulation for CPB in the setting of CNS involvement requires careful decision-making; haemorrhagic transformation is a major risk. Neurological evaluation and CT/MRI brain mandatory pre-operatively.
Renal Complications
- Embolic renal infarction
- Immune complex glomerulonephritis
- Aminoglycoside nephrotoxicity
- Anaesthetic implication: optimise renal function; avoid nephrotoxins; post-CPB acute kidney injury risk is high
Pulmonary Complications (right-sided IE)
- Septic pulmonary emboli - bilateral nodular infiltrates, cavitation
- ARDS in septic patients
- Anaesthetic implication: hypoxaemia, high ventilation requirements, V/Q mismatch
Splenic Complications
- Splenic emboli, infarction, abscess
- Risk of splenic rupture
- Pre-operative CT abdomen recommended
Coagulopathy (Hermanns H et al. J Clin Med 2023 - PMID 37685829)
- Thrombocytopaenia - immune mediated + consumptive
- DIC in fulminant S. aureus IE
- Anaesthetic implication: pre-op assessment of coagulation profile, platelet count, fibrinogen; anticipate massive transfusion requirement in surgery
7. ANTIBIOTIC THERAPY - KEY PRINCIPLES
(AHA 2015 Scientific Statement + ESC 2023 Guidelines)
| Organism | Preferred Agent | Duration |
|---|---|---|
| Viridans streptococci (penicillin-sensitive) | Penicillin G or ceftriaxone | 4 weeks (native), 6 weeks (prosthetic) |
| S. aureus (MSSA), native valve | Nafcillin/oxacillin or cefazolin | 6 weeks |
| S. aureus (MRSA) | Vancomycin | 6 weeks |
| Enterococci | Penicillin/ampicillin + gentamicin OR ampicillin + ceftriaxone | 4-6 weeks |
| HACEK organisms | Ceftriaxone | 4 weeks |
| S. aureus PVE (MSSA) | Nafcillin/oxacillin + rifampin + gentamicin | ≥6 weeks |
| Fungi | Liposomal amphotericin B + azole | Surgery usually required |
Perioperative antibiotic implications:
- Continue therapeutic antibiotics through surgery
- Do NOT wait for completion of antibiotics before urgent/emergency surgery
- Rifampin interactions: potent CYP450 inducer - affects volatile agent metabolism, opioid metabolism (reduces fentanyl/methadone levels)
- Vancomycin: requires renal dose adjustment; "Red man syndrome" with rapid infusion
8. SURGICAL INDICATIONS
(AHA/ACC 2021 Valvular Heart Disease Guidelines; ESC 2023 IE Guidelines)
URGENT/EMERGENT Surgery (within hours)
| Indication | Rationale |
|---|---|
| Acute MR or AR with haemodynamic instability (pulmonary oedema, cardiogenic shock) | No time for medical stabilisation |
| Fungal IE or highly resistant organisms | Medical therapy alone rarely curative |
EARLY Surgery (within days, during same hospitalisation)
| Indication | Notes |
|---|---|
| Heart failure from valvular regurgitation/obstruction | Most common indication |
| Uncontrolled infection: abscess, fistula, enlarging vegetation, persistent fever >5-7 days on appropriate antibiotics | S. aureus, fungi particularly aggressive |
| Large vegetation >10mm on mitral valve with prior embolic event or severe valvular stenosis | Emboli prevention |
| Prosthetic valve endocarditis (most PVE = early surgery) | Higher mortality with medical management alone |
| S. aureus PVE, fungi, Gram-negative bacilli | Aggressive pathogens |
| Complete heart block, annular abscess, destructive penetrating lesions | Perivalvular extension |
DELAYED Surgery
- Neurological complications: if embolic stroke without haemorrhage - can operate within 72 hours for urgent indications; haemorrhagic stroke requires 4+ weeks delay to allow CNS healing before CPB anticoagulation
Braunwald's: "Recidivism is the leading cause of death among intravenous drug users who underwent cardiac surgery for IE" - careful patient selection in PWID.
9. PERIOPERATIVE ANAESTHETIC MANAGEMENT OF IE SURGERY
Pre-operative Assessment
Cardiac assessment:
- Echocardiography (TTE + TEE) - characterise vegetation, valve dysfunction, EF, RWMA, pericardial effusion
- New AV block or bundle branch block (ECG) - suggests aortic root/perivalvular abscess
- Coronary angiography if age >40 or high cardiovascular risk (? coronary emboli)
- BNP/NT-proBNP - degree of heart failure
- Blood cultures - at least 3 sets before antibiotics; note current antibiotic regimen
Neurological assessment:
- CT/MRI brain mandatory - exclude haemorrhagic stroke, abscess, mycotic aneurysm
- If large haemorrhagic stroke: consider delay or discuss risk-benefit of CPB anticoagulation
Haematological/coagulation assessment:
- FBC (anaemia, thrombocytopaenia), coagulation screen, fibrinogen
- Prepare blood products: RBC, FFP, platelets, cryoprecipitate, fibrinogen concentrate
- Group and cross-match
Infectious/metabolic:
- CRP, PCT, WCC - degree of sepsis
- Renal function (creatinine, GFR) - affects drug dosing (vancomycin, aminoglycosides)
- Blood glucose - sepsis-induced hyperglycaemia
- Identify current antibiotics and continue them through surgery
Intraoperative Management
Monitoring (standard + additional):
- 5-lead ECG (detect new AV block intraoperatively)
- Arterial line (pre-induction) - beat-to-beat BP monitoring
- Central venous catheter
- Pulmonary artery catheter - if significant heart failure/cardiogenic shock
- Intraoperative TEE - MANDATORY - guides surgical decision-making, assesses repair adequacy, detects residual lesions, monitors ventricular function post-bypass
- Near-infrared spectroscopy (NIRS/cerebral oximetry) - particularly relevant given embolic stroke risk
- Temperature (core and peripheral)
Induction strategy:
- Haemodynamic goals depend on valve lesion:
| Lesion | HR | SVR | Preload | Contractility |
|---|---|---|---|---|
| Severe AR | Normal-fast (avoid bradycardia) | Low-normal | Normal-↑ | Support |
| Severe MR | Normal-fast | Low-normal | Normal | Support |
| Aortic stenosis (concurrent) | Normal-slow | Maintain | ↑ | Support |
| Septic cardiomyopathy | Normal | Support (vasopressors) | Optimise | Inotropes |
- Haemodynamically unstable patients: ketamine or etomidate for induction (not propofol bolus)
- Opioid-based induction (fentanyl/sufentanil) attenuates sympathetic response
- Avoid sudden drops in SVR (especially in severe AR, critical AS)
- Septic patients may have vasodilatory shock - early vasopressors (norepinephrine) as bridge to CPB
Antibiotic prophylaxis for skin incision - cefazolin or vancomycin (if MRSA risk); continue therapeutic antibiotics
Cardiopulmonary Bypass considerations:
- Coagulopathy management: baseline TEG/ROTEM pre-bypass; anticipate significant bleeding post-bypass in septic patients with DIC or thrombocytopaenia
- Pericardial irrigation with antibiotic solutions (betadine wash) where required
- Debridement + reconstruction vs valve replacement - surgical decision guided by intraoperative TEE
- Left heart vents to avoid air embolism
- CPB pump prime may need FFP/platelets in severe coagulopathy
- Anti-fibrinolytics (tranexamic acid) - standard of care in cardiac surgery to reduce bleeding
Neurological protection:
- Moderate hypothermia (32-34°C) where CNS embolism is suspected
- Maintain MAP 60-80 mmHg on CPB to maintain cerebral perfusion
- Cerebral oximetry monitoring - respond to desaturation with haematocrit optimisation, MAP adjustment
- Avoid air emboli (meticulous deairing)
Post-bypass assessment (TEE):
- Adequacy of valve repair or prosthesis function
- Exclude residual perivalvular leak
- Biventricular function (LV + RV)
- Presence of new RWMA (coronary air embolism)
- Residual vegetation? (rare - surgical debridement should be complete)
- Pericardial effusion / haematoma
Post-operative ICU Management
- Continue IV antibiotics (therapeutic course usually ≥4-6 weeks total)
- Monitor for:
- New AV block (post-aortic root repair) - temporary epicardial pacing wires mandatory
- Residual valve dysfunction (daily clinical assessment + repeat echo if needed)
- Renal function - AKI post-CPB compounded by sepsis and nephrotoxic antibiotics
- Neurological deterioration - post-embolic stroke or new emboli
- Bleeding - TEG/ROTEM guided haemostasis
- Blood glucose control (tight insulin protocol)
- Infection surveillance - bacteraemia recurrence, wound infection
10. ANTIBIOTIC PROPHYLAXIS FOR ELECTIVE PROCEDURES IN HIGH-RISK PATIENTS
(AHA 2021 Scientific Statement Update)
Conditions Warranting Prophylaxis Before Invasive Dental Procedures:
- Prosthetic cardiac valve (including TAVR)
- Prior episode of IE
- Cardiac valve repair using prosthetic material (within 6 months)
- Unrepaired cyanotic CHD
- Repaired CHD with residual defects adjacent to prosthetic material
- Cardiac transplant with valve regurgitation
- Ventricular assist devices and implantable artificial hearts (NEW in 2021)
Drug Regimen:
- First line: Amoxicillin 2g orally 30-60 min before procedure
- Penicillin allergy (true): Doxycycline 100mg OR azithromycin/clarithromycin 500mg (clindamycin removed from 2021 guidelines due to C. difficile risk)
- If unable to take oral: Ampicillin 2g IM/IV OR cefazolin/ceftriaxone 1g IM/IV
Key change 2021: Clindamycin NO LONGER recommended as alternative. Doxycycline added. Allergy testing recommended - 90% of patients with penicillin allergy history will have negative skin testing and can receive amoxicillin.
Critical point for anaesthesiologists: Intubation itself (laryngoscopy, nasotracheal intubation) causes bacteraemia. For high-risk patients undergoing any non-cardiac surgery, the role of prophylaxis is nuanced - current AHA guidelines focus prophylaxis on dental procedures only; GI and respiratory tract procedures do NOT routinely require IE prophylaxis.
11. SPECIAL SITUATIONS
Right-Sided IE (IV Drug Users)
- Tricuspid valve most common; staphylococcal (70%)
- Septic pulmonary emboli - bilateral cavitating nodules
- Better prognosis than left-sided IE (mortality ~10% vs 25-45%)
- Surgical approach: tricuspid valvectomy (without replacement) may be preferred in active drug users to reduce re-infection risk
- Anaesthetic concern: severe TR on induction - RV failure possible; IV line on the arm used for drug injection may be infected
CIED-Related IE
- Vegetation on lead or device pocket
- Complete device removal (leads + generator) is standard of care
- Lead extraction: high risk of pulmonary embolism of vegetative debris during extraction
- Vegetations >2.5 cm: consider open surgical extraction
- Post-extraction pacing strategy must be planned pre-operatively
- Anaesthetic: general anaesthesia + TEE; defibrillator pads on before removing device; temporary pacing wire on standby
IE Post-TAVR
- More common with self-expandable valves
- Orotracheal intubation is a recognised risk factor for TAVR-IE
- Staphylococci and enterococci predominant
- Very high mortality; surgery often required but technically challenging
Pregnant Patient with IE
- Rare but high maternal and foetal mortality
- TEE preferred over TTE for diagnosis
- Surgery on CPB: increased foetal mortality (10-30%); use normothermic bypass if possible; pulsatile flow; maintain high flow rates; avoid hypotension
- Multidisciplinary team: cardiology, obstetrics, cardiac surgery, neonatology
12. SUMMARY TABLE - ANAESTHESIOLOGIST'S QUICK REFERENCE
| Domain | Key Points |
|---|---|
| Diagnosis | Modified Duke criteria; TEE > TTE (sensitivity 95% vs 45%) |
| Microbiology | S. aureus (healthcare), viridans strep (community), MRSA in IVDU |
| Complications | HF, stroke, abscess/AV block, renal failure, coagulopathy, mycotic aneurysm |
| Surgical urgency | Emergency (cardiogenic shock), Early (HF, uncontrolled infection, abscess), Delayed (haemorrhagic stroke >4 weeks) |
| Induction | Haemodynamic goals dictated by valve lesion; ketamine/etomidate in instability |
| Monitoring | Arterial line pre-induction, intraoperative TEE mandatory, cerebral oximetry |
| CPB | TEG/ROTEM guided; expect coagulopathy; TXA; continue antibiotics |
| Post-op | Epicardial pacing wires mandatory (AV block risk); renal monitoring; 4-6 weeks IV antibiotics |
| Prophylaxis 2021 | Dental procedures in high-risk only; amoxicillin 2g; clindamycin removed; doxycycline added |
Sources:
- Braunwald's Heart Disease (12th ed) - Chapter 80: Infective Endocarditis
- Fuster & Hurst's The Heart (15th ed) - Chapter 33: Infective Endocarditis
- Robbins & Cotran Pathologic Basis of Disease - Chapter 12: Heart
- Goldman-Cecil Medicine: IE section
- Hermanns H et al. J Clin Med 2023: "Perioperative Complications in Infective Endocarditis" (PMID 37685829)
- Li JS et al. Clin Infect Dis 2000;30:633 - Modified Duke Criteria
- AHA 2021 Scientific Statement: Prophylaxis update (Baddour LM et al.)
- ESC 2023 Guidelines on IE Management
Feel free to ask about any specific aspect you want me to go deeper on - haemodynamic management of specific valve lesions, CPB strategies, specific antibiotic regimens, neurological complications, or paediatric/pregnant IE. I'll pull the relevant sections from Miller's, Barash, or Kaplan's Cardiac Anaesthesia as applicable.
This is a shared conversation. Sign in to Orris to start your own chat.